CryoLife suspends processing method after FDA letter
This article was originally published in Clinica
Executive Summary
CryoLife, of Kennesaw, Georgia, has voluntarily suspended the use of its SynerGraft technology in the processing of its CryoValve allograft heart valves and CryoVein femoral veins for arteriovenous (A-V) access. It will use its original processing methods for these products instead.